###begin article-title 0
The 894G>T variant in the endothelial nitric oxide synthase gene and spina bifida risk
###end article-title 0
###begin p 1
###xml 72 76 72 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 197 201 197 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 412 416 412 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 436 441 436 441 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR</italic>
###xml 550 554 550 554 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 756 760 756 760 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 774 777 774 775 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#935;</italic>
###xml 777 778 775 776 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 787 788 785 786 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 822 827 820 825 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR</italic>
###xml 895 899 893 897 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 1056 1060 1054 1058 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 255 263 <span type="species:ncbi:9606">children</span>
###xml 619 627 <span type="species:ncbi:9606">children</span>
###xml 1137 1142 <span type="species:ncbi:9606">child</span>
The 894G>T single nucleotide polymorphism (SNP) in the endothelial NOS (NOS3) gene, has recently been associated with embryonic spina bifida risk. In this study, a possible association between the NOS3 894G>T SNP and spina bifida risk in both mothers and children in a Dutch population was examined using both a case-control design and a transmission disequilibrium test (TDT). Possible interactions between the NOS3 894G>T SNP and the MTHFR 677C>T SNP, elevated plasma homocysteine, and decreased plasma folate concentrations were also studied. The NOS3 894TT genotype did not increase spina bifida risk in mothers or children (OR 1.50, 95%CI 0.71-3.19 and OR 1.78, 95%CI 0.75-4.25, respectively). The TDT demonstrated no preferential transmission of the NOS3 894T allele (Chi2 = 0.06, P = 0.81). In combination with the MTHFR 677TT genotype or elevated plasma homocysteine concentrations, the NOS3 894GT/TT genotype increased maternal spina bifida risk (OR 4.52, 95%CI 1.55-13.22 and OR 3.38, 95%CI 1.46-7.84, respectively). In our study population, the NOS3 894GT/TT genotype might be a risk factor for having a spina bifida affected child in mothers who already have an impaired homocysteine metabolism.
###end p 1
###begin title 2
Keywords
###end title 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 242 246 242 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">2006</xref>
###xml 371 375 371 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">1994</xref>
###xml 497 501 497 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">2002</xref>
###xml 587 591 587 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">2003</xref>
###xml 749 753 749 753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">2001</xref>
###xml 795 799 795 799 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">2006</xref>
###xml 813 817 813 817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">2004</xref>
###xml 439 444 <span type="species:ncbi:9031">chick</span>
Nitric oxide synthase (NOS) catalyzes the generation of nitric oxide (NO), an important signaling molecule that mediates many of its biological effects by activating the enzyme guanylyl cyclase, thereby increasing cyclic GMP synthesis (Murad 2006). Besides its important role in cardiovascular control, NO has been suggested to play a role in development (Lee and Juchau 1994). NO has been demonstrated to be present in the neural tube of chick embryos at the time of neurulation (Traister et al. 2002) and regulates the balance between mitosis and programmed cell death (Plachta et al. 2003). Other studies show that NO can inhibit methionine synthase (MTR) enzyme activity, thereby interfering with homocysteine remethylation (Danishpajooh et al. 2001) and proper neurulation (Nachmany et al. 2006; Weil et al. 2004).
###end p 4
###begin p 5
###xml 98 102 98 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 142 146 142 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">1999</xref>
###xml 282 286 282 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2003</xref>
###xml 333 337 333 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 439 443 439 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">2004</xref>
The 894G>T single nucleotide polymorphism (SNP) in the endothelial-derived nitric oxide synthase (NOS3) gene, identified by Hingorani et al. (1999), was shown to be associated with elevated plasma homocysteine levels in nonsmokers with low serum folate concentrations (Brown et al. 2003). More recently, it was demonstrated that the NOS3 894GT genotype is an embryonic risk factor for spina bifida (OR 1.63, 95%CI 1.09-2.42) (Brown et al. 2004).
###end p 5
###begin p 6
###xml 52 56 52 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 210 214 210 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 338 342 338 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 362 367 362 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR</italic>
###xml 110 118 <span type="species:ncbi:9606">children</span>
In this study, we examined the relation between the NOS3 894G>T SNP and spina bifida risk in both mothers and children using a case-control design and a transmission disequilibrium test (TDT). An effect of the NOS3 894G>T SNP on plasma homocysteine or plasma folate concentration was examined as well as possible interactions between the NOS3 894G>T SNP and the MTHFR 677C>T SNP, elevated plasma homocysteine, and decreased plasma folate concentrations.
###end p 6
###begin title 7
Materials and methods
###end title 7
###begin title 8
Study population
###end title 8
###begin p 9
###xml 80 84 80 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">2006</xref>
###xml 395 396 393 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 441 442 437 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 323 331 <span type="species:ncbi:9606">patients</span>
###xml 336 341 <span type="species:ncbi:9606">girls</span>
###xml 349 353 <span type="species:ncbi:9606">boys</span>
The study population has been described in detail before (van der Linden et al. 2006). Briefly, the study population was recruited in collaboration with the BOSK and was extended by a group from the Pediatric Neurology Department of the Radboud University Nijmegen Medical Center. The study group included 109 spina bifida patients (61 girls and 48 boys, mean age 16.4 +/- 11.3), their mothers (n = 121, mean age 42.9 +/- 10.9) and fathers (n = 103, mean age 44.9 +/- 10.2).
###end p 9
###begin p 10
###xml 112 116 112 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">1995</xref>
###xml 337 341 333 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">1999</xref>
###xml 165 170 <span type="species:ncbi:9606">women</span>
###xml 262 270 <span type="species:ncbi:9606">children</span>
###xml 276 281 <span type="species:ncbi:9606">girls</span>
###xml 290 294 <span type="species:ncbi:9606">boys</span>
###xml 348 356 <span type="species:ncbi:9606">children</span>
###xml 422 430 <span type="species:ncbi:9606">children</span>
The control group consisted of 500 volunteers recruited from a general practice in The Hague (den Heijer et al. 1995). In the present study we only included the 292 women from this control group (mean age 50.6 +/- 13.5). The pediatric control group included 234 children (119 girls and 115 boys, mean age 8.4 +/- 6.4) (van Beynum et al. 1999). The children of secondary school age were healthy volunteers, and the younger children were, for ethical reasons, recruited in a hospital setting. The local medical ethics committee approved the study.
###end p 10
###begin p 11
###xml 47 55 <span type="species:ncbi:9606">patients</span>
###xml 95 100 <span type="species:ncbi:9606">women</span>
For the present study, DNA of 102 spina bifida patients, 116 mothers, 101 fathers, 265 control women and 211 pediatric controls was available for genotyping.
###end p 11
###begin title 12
Biochemical determinations
###end title 12
###begin p 13
###xml 156 160 156 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">1995</xref>
Plasma total homocysteine concentration was measured in EDTA plasma by HPLC and fluorescence detection, as previously described by te Poele-Pothoff et al. (1995).
###end p 13
###begin p 14
Plasma folate concentration was determined using the Dualcount Solid Phase Boil Radio assay (Diagnostic Product Corporation, Los Angeles, CA).
###end p 14
###begin title 15
PCR amplification and genotype determination
###end title 15
###begin p 16
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 68 72 68 72 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">1999</xref>
###xml 197 200 191 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mbo</italic>
NOS3 894G>T genotyping was performed according to Hingorani et al. (1999). Primer annealing took place at a temperature of 58degreesC. The PCR product of 206 bp was cut with the restriction enzyme MboI, which cuts the T allele in fragments of 119 and 87 bp.
###end p 16
###begin title 17
Statistical analyses
###end title 17
###begin title 18
Case-control study
###end title 18
###begin p 19
Odds ratios (ORs) and their 95% confidence intervals (95%CI) were calculated by means of logistic regression analysis.
###end p 19
###begin p 20
###xml 18 22 18 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
The effect of the NOS3 894G>T SNP on plasma homocysteine and plasma folate concentration was studied by means of linear regression analysis. Since the distributions of plasma homocysteine and plasma folate concentrations are positively skewed, these variables were logarithmically transformed prior to linear regression analysis.
###end p 20
###begin p 21
Deviation from Hardy-Weinberg equilibrium was calculated to assess the accuracy of the genotyping assay.
###end p 21
###begin p 22
###xml 102 106 102 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">2003</xref>
###xml 232 233 232 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
The power of the case-control study was calculated using the Genetic Power Calculator (Purcell et al. 2003). All tests were performed using SPSS software package version 12.0.1. Statistical significance was accepted at a two-tailed P < 0.05 or 95%CI of an odds ratio that did not include 1.0.
###end p 22
###begin title 23
Transmission disequilibrium test
###end title 23
###begin p 24
###xml 25 29 25 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 270 274 270 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">1993</xref>
###xml 364 368 364 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">2003</xref>
###xml 66 74 <span type="species:ncbi:9606">patients</span>
The relation between the NOS3 894G>T genotype of the spina bifida patients and spina bifida risk was assessed by evaluating the transmission of alleles from heterozygous parents to their affected offspring using the TDT, a family-based association test (Spielman et al. 1993). The power of the TDT was calculated using the Genetic Power Calculator (Purcell et al. 2003).
###end p 24
###begin title 25
Results
###end title 25
###begin title 26
Case-control study
###end title 26
###begin p 27
###xml 4 8 4 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 211 212 211 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 310 311 310 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 342 346 342 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 370 374 370 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 443 447 443 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 488 492 488 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 516 520 516 520 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 586 590 586 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 611 615 611 615 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 782 786 782 786 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 834 838 834 838 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 975 982 975 982 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 986 990 986 990 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 982 1102 982 1102 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="28">The <italic>NOS3</italic> 894G&gt;T genotype distribution and unadjusted ORs in mothers of a spina bifida affected child and female controls</p>
###xml 982 1102 982 1102 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="28">The <italic>NOS3</italic> 894G&gt;T genotype distribution and unadjusted ORs in mothers of a spina bifida affected child and female controls</p></caption>
###xml 1102 1106 1102 1106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 1102 1113 1102 1113 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>NOS3</italic> 894G&gt;T</th>
###xml 1113 1124 1113 1124 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Mothers (%)</th>
###xml 1124 1143 1124 1143 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Female controls (%)</th>
###xml 1143 1153 1143 1153 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">OR (95%CI)</th>
###xml 1102 1153 1102 1153 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left"><italic>NOS3</italic> 894G&gt;T</th><th align="left">Mothers (%)</th><th align="left">Female controls (%)</th><th align="left">OR (95%CI)</th></tr>
###xml 1102 1153 1102 1153 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left"><italic>NOS3</italic> 894G&gt;T</th><th align="left">Mothers (%)</th><th align="left">Female controls (%)</th><th align="left">OR (95%CI)</th></tr></thead>
###xml 1153 1155 1153 1155 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">GG</td>
###xml 1155 1164 1155 1164 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">49 (42.6)</td>
###xml 1164 1174 1164 1174 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">130 (50.2)</td>
###xml 1175 1176 1175 1176 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1174 1176 1174 1176 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1<sup>a</sup></td>
###xml 1153 1176 1153 1176 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">GG</td><td align="left">49 (42.6)</td><td align="left">130 (50.2)</td><td align="left">1<sup>a</sup></td></tr>
###xml 1176 1178 1176 1178 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">GT</td>
###xml 1178 1187 1178 1187 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">53 (46.1)</td>
###xml 1187 1197 1187 1197 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">106 (40.9)</td>
###xml 1197 1213 1197 1213 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1.33 (0.83&#8211;2.11)</td>
###xml 1176 1213 1176 1213 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">GT</td><td align="left">53 (46.1)</td><td align="left">106 (40.9)</td><td align="left">1.33 (0.83&#8211;2.11)</td></tr>
###xml 1213 1215 1213 1215 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">TT</td>
###xml 1215 1224 1215 1224 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">13 (11.3)</td>
###xml 1224 1232 1224 1232 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">23 (8.9)</td>
###xml 1232 1248 1232 1248 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1.50 (0.71&#8211;3.19)</td>
###xml 1213 1248 1213 1248 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">TT</td><td align="left">13 (11.3)</td><td align="left">23 (8.9)</td><td align="left">1.50 (0.71&#8211;3.19)</td></tr>
###xml 1153 1248 1153 1248 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">GG</td><td align="left">49 (42.6)</td><td align="left">130 (50.2)</td><td align="left">1<sup>a</sup></td></tr><tr><td align="left">GT</td><td align="left">53 (46.1)</td><td align="left">106 (40.9)</td><td align="left">1.33 (0.83&#8211;2.11)</td></tr><tr><td align="left">TT</td><td align="left">13 (11.3)</td><td align="left">23 (8.9)</td><td align="left">1.50 (0.71&#8211;3.19)</td></tr></tbody>
###xml 1102 1248 1102 1248 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left"><italic>NOS3</italic> 894G&gt;T</th><th align="left">Mothers (%)</th><th align="left">Female controls (%)</th><th align="left">OR (95%CI)</th></tr></thead><tbody><tr><td align="left">GG</td><td align="left">49 (42.6)</td><td align="left">130 (50.2)</td><td align="left">1<sup>a</sup></td></tr><tr><td align="left">GT</td><td align="left">53 (46.1)</td><td align="left">106 (40.9)</td><td align="left">1.33 (0.83&#8211;2.11)</td></tr><tr><td align="left">TT</td><td align="left">13 (11.3)</td><td align="left">23 (8.9)</td><td align="left">1.50 (0.71&#8211;3.19)</td></tr></tbody></table>
###xml 1248 1249 1248 1249 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1248 1264 1248 1264 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="29"><sup>a</sup>Reference group</p>
###xml 1248 1264 1248 1264 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="29"><sup>a</sup>Reference group</p></table-wrap-foot>
###xml 975 1264 975 1264 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="28">The <italic>NOS3</italic> 894G&gt;T genotype distribution and unadjusted ORs in mothers of a spina bifida affected child and female controls</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><italic>NOS3</italic> 894G&gt;T</th><th align="left">Mothers (%)</th><th align="left">Female controls (%)</th><th align="left">OR (95%CI)</th></tr></thead><tbody><tr><td align="left">GG</td><td align="left">49 (42.6)</td><td align="left">130 (50.2)</td><td align="left">1<sup>a</sup></td></tr><tr><td align="left">GT</td><td align="left">53 (46.1)</td><td align="left">106 (40.9)</td><td align="left">1.33 (0.83&#8211;2.11)</td></tr><tr><td align="left">TT</td><td align="left">13 (11.3)</td><td align="left">23 (8.9)</td><td align="left">1.50 (0.71&#8211;3.19)</td></tr></tbody></table><table-wrap-foot><p textid="29"><sup>a</sup>Reference group</p></table-wrap-foot></table-wrap>
###xml 87 92 <span type="species:ncbi:9606">child</span>
###xml 760 765 <span type="species:ncbi:9606">child</span>
###xml 1077 1082 <span type="species:ncbi:9606">child</span>
The NOS3 894G>T genotype could be determined in 115 mothers of a spina bifida affected child and in 259 female controls. Genotype distribution did not differ from that expected under Hardy-Weinberg equilibrium (P = 0.83), and the power to detect a twofold increase in maternal spina bifida risk was 59%. Table 1 demonstrates that neither the NOS3 894GT genotype nor the NOS3 894TT genotype increased maternal spina bifida risk relative to the NOS3 894GG genotype. Since the effect of the NOS3 894GT genotype and the NOS3 894TT genotype on spina bifida risk was the same relative to the NOS3 894GG genotype, the NOS3 894GT and TT genotypes were combined to increase power, which resulted in a nonsignificant 36% increased risk of having a spina bifida affected child relative to the NOS3 894GG genotype (OR 1.36, 95%CI 0.87-2.11). The NOS3 894G>T SNP was not associated with plasma homocysteine or plasma folate concentrations in mothers and female controls (data not shown). Table 1The NOS3 894G>T genotype distribution and unadjusted ORs in mothers of a spina bifida affected child and female controlsNOS3 894G>TMothers (%)Female controls (%)OR (95%CI)GG49 (42.6)130 (50.2)1aGT53 (46.1)106 (40.9)1.33 (0.83-2.11)TT13 (11.3)23 (8.9)1.50 (0.71-3.19)aReference group
###end p 27
###begin p 28
###xml 4 8 4 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 95 100 <span type="species:ncbi:9606">child</span>
The NOS3 894G>T genotype distribution and unadjusted ORs in mothers of a spina bifida affected child and female controls
###end p 28
###begin p 29
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
aReference group
###end p 29
###begin p 30
###xml 56 60 56 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 111 115 111 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 213 214 213 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 264 268 264 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 336 340 336 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 371 372 371 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 389 393 389 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 484 488 484 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 563 567 563 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 676 680 676 680 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 818 822 818 822 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 896 903 896 903 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;2</label>
###xml 907 911 907 911 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 903 1007 903 1007 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="31">The <italic>NOS3</italic> 894G&gt;T genotype distribution and unadjusted ORs in spina bifida patients and pediatric controls</p>
###xml 903 1007 903 1007 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="31">The <italic>NOS3</italic> 894G&gt;T genotype distribution and unadjusted ORs in spina bifida patients and pediatric controls</p></caption>
###xml 1007 1011 1007 1011 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 1007 1018 1007 1018 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>NOS3</italic> 894G&gt;T</th>
###xml 1018 1033 1018 1033 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">SB patients (%)</th>
###xml 1033 1055 1033 1055 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Pediatric controls (%)</th>
###xml 1055 1065 1055 1065 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">OR (95%CI)</th>
###xml 1007 1065 1007 1065 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left"><italic>NOS3</italic> 894G&gt;T</th><th align="left">SB patients (%)</th><th align="left">Pediatric controls (%)</th><th align="left">OR (95%CI)</th></tr>
###xml 1007 1065 1007 1065 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left"><italic>NOS3</italic> 894G&gt;T</th><th align="left">SB patients (%)</th><th align="left">Pediatric controls (%)</th><th align="left">OR (95%CI)</th></tr></thead>
###xml 1065 1067 1065 1067 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">GG</td>
###xml 1067 1076 1067 1076 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">39 (41.1)</td>
###xml 1076 1086 1076 1086 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">111 (53.6)</td>
###xml 1087 1088 1087 1088 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1086 1088 1086 1088 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1<sup>a</sup></td>
###xml 1065 1088 1065 1088 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">GG</td><td align="left">39 (41.1)</td><td align="left">111 (53.6)</td><td align="left">1<sup>a</sup></td></tr>
###xml 1088 1090 1088 1090 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">GT</td>
###xml 1090 1099 1090 1099 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">46 (48.4)</td>
###xml 1099 1108 1099 1108 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">80 (38.6)</td>
###xml 1108 1124 1108 1124 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1.64 (0.98&#8211;2.74)</td>
###xml 1088 1124 1088 1124 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">GT</td><td align="left">46 (48.4)</td><td align="left">80 (38.6)</td><td align="left">1.64 (0.98&#8211;2.74)</td></tr>
###xml 1124 1126 1124 1126 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">TT</td>
###xml 1126 1135 1126 1135 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">10 (10.5)</td>
###xml 1135 1143 1135 1143 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">16 (7.7)</td>
###xml 1143 1159 1143 1159 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1.78 (0.75&#8211;4.25)</td>
###xml 1124 1159 1124 1159 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">TT</td><td align="left">10 (10.5)</td><td align="left">16 (7.7)</td><td align="left">1.78 (0.75&#8211;4.25)</td></tr>
###xml 1065 1159 1065 1159 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">GG</td><td align="left">39 (41.1)</td><td align="left">111 (53.6)</td><td align="left">1<sup>a</sup></td></tr><tr><td align="left">GT</td><td align="left">46 (48.4)</td><td align="left">80 (38.6)</td><td align="left">1.64 (0.98&#8211;2.74)</td></tr><tr><td align="left">TT</td><td align="left">10 (10.5)</td><td align="left">16 (7.7)</td><td align="left">1.78 (0.75&#8211;4.25)</td></tr></tbody>
###xml 1007 1159 1007 1159 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left"><italic>NOS3</italic> 894G&gt;T</th><th align="left">SB patients (%)</th><th align="left">Pediatric controls (%)</th><th align="left">OR (95%CI)</th></tr></thead><tbody><tr><td align="left">GG</td><td align="left">39 (41.1)</td><td align="left">111 (53.6)</td><td align="left">1<sup>a</sup></td></tr><tr><td align="left">GT</td><td align="left">46 (48.4)</td><td align="left">80 (38.6)</td><td align="left">1.64 (0.98&#8211;2.74)</td></tr><tr><td align="left">TT</td><td align="left">10 (10.5)</td><td align="left">16 (7.7)</td><td align="left">1.78 (0.75&#8211;4.25)</td></tr></tbody></table>
###xml 1159 1160 1159 1160 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1159 1175 1159 1175 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="32"><sup>a</sup>Reference group</p>
###xml 1159 1175 1159 1175 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="32"><sup>a</sup>Reference group</p></table-wrap-foot>
###xml 896 1175 896 1175 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab2"><label>Table&#160;2</label><caption><p textid="31">The <italic>NOS3</italic> 894G&gt;T genotype distribution and unadjusted ORs in spina bifida patients and pediatric controls</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><italic>NOS3</italic> 894G&gt;T</th><th align="left">SB patients (%)</th><th align="left">Pediatric controls (%)</th><th align="left">OR (95%CI)</th></tr></thead><tbody><tr><td align="left">GG</td><td align="left">39 (41.1)</td><td align="left">111 (53.6)</td><td align="left">1<sup>a</sup></td></tr><tr><td align="left">GT</td><td align="left">46 (48.4)</td><td align="left">80 (38.6)</td><td align="left">1.64 (0.98&#8211;2.74)</td></tr><tr><td align="left">TT</td><td align="left">10 (10.5)</td><td align="left">16 (7.7)</td><td align="left">1.78 (0.75&#8211;4.25)</td></tr></tbody></table><table-wrap-foot><p textid="32"><sup>a</sup>Reference group</p></table-wrap-foot></table-wrap>
###xml 19 27 <span type="species:ncbi:9606">patients</span>
###xml 315 323 <span type="species:ncbi:9606">children</span>
###xml 869 877 <span type="species:ncbi:9606">children</span>
###xml 976 984 <span type="species:ncbi:9606">patients</span>
###xml 1021 1029 <span type="species:ncbi:9606">patients</span>
In 95 spina bifida patients and 207 pediatric controls, NOS3 894G>T genotyping was performed successfully. The NOS3 894G>T genotype distribution did not differ from that expected under Hardy-Weinberg equilibrium (P = 0.76), and the power of the study was 51%. The NOS3 894GT genotype increased spina bifida risk in children whereas the NOS3 894TT genotype did not (Table 2). Combining the NOS3 894GT and 894TT genotypes resulted in a 66% increase in spina bifida risk relative to the NOS3 894GG genotype (OR 1.66, 95%CI 1.02-2.72). In the pediatric controls, the NOS3 894GT and 894TT genotypes were associated with increased plasma homocysteine concentrations relative to the NOS3 894GG genotype (14.7% increase, 95%CI 4.2-26.2% and 23.5% increase, 95%CI 3.9-46.8%, respectively). There was no association between the NOS3 894G>T SNP and plasma folate concentration in children (data not shown). Table 2The NOS3 894G>T genotype distribution and unadjusted ORs in spina bifida patients and pediatric controlsNOS3 894G>TSB patients (%)Pediatric controls (%)OR (95%CI)GG39 (41.1)111 (53.6)1aGT46 (48.4)80 (38.6)1.64 (0.98-2.74)TT10 (10.5)16 (7.7)1.78 (0.75-4.25)aReference group
###end p 30
###begin p 31
###xml 4 8 4 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 73 81 <span type="species:ncbi:9606">patients</span>
The NOS3 894G>T genotype distribution and unadjusted ORs in spina bifida patients and pediatric controls
###end p 31
###begin p 32
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
aReference group
###end p 32
###begin title 33
Transmission disequilibrium test
###end title 33
###begin p 34
###xml 193 197 193 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 260 263 260 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#935;</italic>
###xml 263 264 261 262 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 274 275 272 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 51 56 <span type="species:ncbi:9606">child</span>
###xml 233 238 <span type="species:ncbi:9606">child</span>
In this study there were 75 complete mother-father-child triads, and the power to detect a twofold increase in spina bifida risk was 32%. In 36 out of 70 informative transmissions (51.4%), the NOS3 894T allele was transmitted to the child, which resulted in a Chi2 of 0.06 (P = 0.81).
###end p 34
###begin title 35
Gene-gene interaction
###end title 35
###begin p 36
###xml 17 21 17 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 46 51 46 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR</italic>
###xml 163 168 163 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR</italic>
###xml 235 240 235 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR</italic>
###xml 283 288 283 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR</italic>
###xml 355 360 355 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR</italic>
###xml 381 385 381 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 491 495 491 495 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 529 534 529 534 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR</italic>
###xml 588 589 588 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">3</xref>
###xml 592 599 592 599 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;3</label>
###xml 653 657 653 657 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 677 682 677 682 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR</italic>
###xml 599 693 599 693 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="37">Maternal spina bifida risk for the combination of the <italic>NOS3</italic> 894G&gt;T SNP and the <italic>MTHFR</italic> 677C&gt;T SNP</p>
###xml 599 693 599 693 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="37">Maternal spina bifida risk for the combination of the <italic>NOS3</italic> 894G&gt;T SNP and the <italic>MTHFR</italic> 677C&gt;T SNP</p></caption>
###xml 693 697 693 697 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 693 704 693 704 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>NOS3</italic> 894G&gt;T</th>
###xml 704 709 704 709 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR</italic>
###xml 704 716 704 716 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>MTHFR</italic> 677C&gt;T</th>
###xml 716 727 716 727 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Mothers (%)</th>
###xml 727 746 727 746 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Female controls (%)</th>
###xml 746 756 746 756 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">OR (95%CI)</th>
###xml 693 756 693 756 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left"><italic>NOS3</italic> 894G&gt;T</th><th align="left"><italic>MTHFR</italic> 677C&gt;T</th><th align="left">Mothers (%)</th><th align="left">Female controls (%)</th><th align="left">OR (95%CI)</th></tr>
###xml 693 756 693 756 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left"><italic>NOS3</italic> 894G&gt;T</th><th align="left"><italic>MTHFR</italic> 677C&gt;T</th><th align="left">Mothers (%)</th><th align="left">Female controls (%)</th><th align="left">OR (95%CI)</th></tr></thead>
###xml 756 758 756 758 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">GG</td>
###xml 758 763 758 763 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">CC/CT</td>
###xml 763 772 763 772 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">42 (38.2)</td>
###xml 772 782 772 782 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">114 (44.0)</td>
###xml 783 784 783 784 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 782 784 782 784 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1<sup>a</sup></td>
###xml 756 784 756 784 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">GG</td><td align="left">CC/CT</td><td align="left">42 (38.2)</td><td align="left">114 (44.0)</td><td align="left">1<sup>a</sup></td></tr>
###xml 784 786 784 786 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">GG</td>
###xml 786 788 786 788 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">TT</td>
###xml 788 795 788 795 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">6 (5.5)</td>
###xml 795 803 795 803 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">16 (6.2)</td>
###xml 803 819 803 819 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1.02 (0.37&#8211;2.77)</td>
###xml 784 819 784 819 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">GG</td><td align="left">TT</td><td align="left">6 (5.5)</td><td align="left">16 (6.2)</td><td align="left">1.02 (0.37&#8211;2.77)</td></tr>
###xml 819 824 819 824 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">GT/TT</td>
###xml 824 829 824 829 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">CC/CT</td>
###xml 829 838 829 838 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">52 (47.3)</td>
###xml 838 848 838 848 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">123 (47.5)</td>
###xml 848 864 848 864 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1.15 (0.71&#8211;1.85)</td>
###xml 819 864 819 864 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">GT/TT</td><td align="left">CC/CT</td><td align="left">52 (47.3)</td><td align="left">123 (47.5)</td><td align="left">1.15 (0.71&#8211;1.85)</td></tr>
###xml 864 869 864 869 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">GT/TT</td>
###xml 869 871 869 871 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">TT</td>
###xml 871 879 871 879 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">10 (9.1)</td>
###xml 879 886 879 886 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">6 (2.3)</td>
###xml 886 903 886 903 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">4.52 (1.55&#8211;13.22)</td>
###xml 864 903 864 903 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">GT/TT</td><td align="left">TT</td><td align="left">10 (9.1)</td><td align="left">6 (2.3)</td><td align="left">4.52 (1.55&#8211;13.22)</td></tr>
###xml 756 903 756 903 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">GG</td><td align="left">CC/CT</td><td align="left">42 (38.2)</td><td align="left">114 (44.0)</td><td align="left">1<sup>a</sup></td></tr><tr><td align="left">GG</td><td align="left">TT</td><td align="left">6 (5.5)</td><td align="left">16 (6.2)</td><td align="left">1.02 (0.37&#8211;2.77)</td></tr><tr><td align="left">GT/TT</td><td align="left">CC/CT</td><td align="left">52 (47.3)</td><td align="left">123 (47.5)</td><td align="left">1.15 (0.71&#8211;1.85)</td></tr><tr><td align="left">GT/TT</td><td align="left">TT</td><td align="left">10 (9.1)</td><td align="left">6 (2.3)</td><td align="left">4.52 (1.55&#8211;13.22)</td></tr></tbody>
###xml 693 903 693 903 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left"><italic>NOS3</italic> 894G&gt;T</th><th align="left"><italic>MTHFR</italic> 677C&gt;T</th><th align="left">Mothers (%)</th><th align="left">Female controls (%)</th><th align="left">OR (95%CI)</th></tr></thead><tbody><tr><td align="left">GG</td><td align="left">CC/CT</td><td align="left">42 (38.2)</td><td align="left">114 (44.0)</td><td align="left">1<sup>a</sup></td></tr><tr><td align="left">GG</td><td align="left">TT</td><td align="left">6 (5.5)</td><td align="left">16 (6.2)</td><td align="left">1.02 (0.37&#8211;2.77)</td></tr><tr><td align="left">GT/TT</td><td align="left">CC/CT</td><td align="left">52 (47.3)</td><td align="left">123 (47.5)</td><td align="left">1.15 (0.71&#8211;1.85)</td></tr><tr><td align="left">GT/TT</td><td align="left">TT</td><td align="left">10 (9.1)</td><td align="left">6 (2.3)</td><td align="left">4.52 (1.55&#8211;13.22)</td></tr></tbody></table>
###xml 903 904 903 904 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 903 919 903 919 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="38"><sup>a</sup>Reference group</p>
###xml 903 919 903 919 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="38"><sup>a</sup>Reference group</p></table-wrap-foot>
###xml 592 919 592 919 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab3"><label>Table&#160;3</label><caption><p textid="37">Maternal spina bifida risk for the combination of the <italic>NOS3</italic> 894G&gt;T SNP and the <italic>MTHFR</italic> 677C&gt;T SNP</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><italic>NOS3</italic> 894G&gt;T</th><th align="left"><italic>MTHFR</italic> 677C&gt;T</th><th align="left">Mothers (%)</th><th align="left">Female controls (%)</th><th align="left">OR (95%CI)</th></tr></thead><tbody><tr><td align="left">GG</td><td align="left">CC/CT</td><td align="left">42 (38.2)</td><td align="left">114 (44.0)</td><td align="left">1<sup>a</sup></td></tr><tr><td align="left">GG</td><td align="left">TT</td><td align="left">6 (5.5)</td><td align="left">16 (6.2)</td><td align="left">1.02 (0.37&#8211;2.77)</td></tr><tr><td align="left">GT/TT</td><td align="left">CC/CT</td><td align="left">52 (47.3)</td><td align="left">123 (47.5)</td><td align="left">1.15 (0.71&#8211;1.85)</td></tr><tr><td align="left">GT/TT</td><td align="left">TT</td><td align="left">10 (9.1)</td><td align="left">6 (2.3)</td><td align="left">4.52 (1.55&#8211;13.22)</td></tr></tbody></table><table-wrap-foot><p textid="38"><sup>a</sup>Reference group</p></table-wrap-foot></table-wrap>
###xml 124 129 <span type="species:ncbi:9606">child</span>
###xml 146 151 <span type="species:ncbi:9606">women</span>
Data on both the NOS3 894G>T genotype and the MTHFR 677C>T genotype were present for 110 mothers of a spina bifida affected child and 259 control women. Since the MTHFR 677CT genotype did not increase spina bifida risk relative to the MTHFR 677CC genotype, we decided to combine the MTHFR 677CC and CT genotypes to increase power. In combination with the MTHFR 677TT genotype, the NOS3 894GT/TT genotype increased the risk of having spina bifida affected offspring 4.5 times relative to the NOS3 894GG genotype combined with the MTHFR 677CC/CT genotype (OR 4.52, 95%CI 1.55-13.22) (Table 3). Table 3Maternal spina bifida risk for the combination of the NOS3 894G>T SNP and the MTHFR 677C>T SNPNOS3 894G>TMTHFR 677C>TMothers (%)Female controls (%)OR (95%CI)GGCC/CT42 (38.2)114 (44.0)1aGGTT6 (5.5)16 (6.2)1.02 (0.37-2.77)GT/TTCC/CT52 (47.3)123 (47.5)1.15 (0.71-1.85)GT/TTTT10 (9.1)6 (2.3)4.52 (1.55-13.22)aReference group
###end p 36
###begin p 37
###xml 54 58 54 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 78 83 78 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR</italic>
Maternal spina bifida risk for the combination of the NOS3 894G>T SNP and the MTHFR 677C>T SNP
###end p 37
###begin p 38
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
aReference group
###end p 38
###begin p 39
###xml 50 54 50 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 81 86 81 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR</italic>
###xml 3 11 <span type="species:ncbi:9606">children</span>
In children, there was no interaction between the NOS3 894GT/TT genotype and the MTHFR 677TT genotype (OR 1.23, 95%CI 0.31-4.91) (data not shown).
###end p 39
###begin title 40
Gene-metabolite interactions
###end title 40
###begin p 41
###xml 10 15 10 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR</italic>
###xml 143 147 143 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 286 290 286 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 369 373 369 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 589 593 587 591 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 741 742 736 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab4" ref-type="table">4</xref>
###xml 745 752 740 747 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;4</label>
###xml 806 810 801 805 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 752 886 747 881 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="42">Maternal spina bifida risk for the combination of the <italic>NOS3</italic> 894G&gt;T SNP and elevated plasma homocysteine concentration, adjusted for age</p>
###xml 752 886 747 881 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="42">Maternal spina bifida risk for the combination of the <italic>NOS3</italic> 894G&gt;T SNP and elevated plasma homocysteine concentration, adjusted for age</p></caption>
###xml 886 890 881 885 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 886 897 881 892 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>NOS3</italic> 894G&gt;T</th>
###xml 922 923 916 917 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 897 923 892 917 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Plasma Hcy conc (&#956;mol/L)<sup>a</sup></th>
###xml 923 934 917 928 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Mothers (%)</th>
###xml 934 953 928 947 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Female controls (%)</th>
###xml 953 963 947 957 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">OR (95%CI)</th>
###xml 886 963 881 957 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left"><italic>NOS3</italic> 894G&gt;T</th><th align="left">Plasma Hcy conc (&#956;mol/L)<sup>a</sup></th><th align="left">Mothers (%)</th><th align="left">Female controls (%)</th><th align="left">OR (95%CI)</th></tr>
###xml 886 963 881 957 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left"><italic>NOS3</italic> 894G&gt;T</th><th align="left">Plasma Hcy conc (&#956;mol/L)<sup>a</sup></th><th align="left">Mothers (%)</th><th align="left">Female controls (%)</th><th align="left">OR (95%CI)</th></tr></thead>
###xml 963 965 957 959 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">GG</td>
###xml 965 971 959 965 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&lt;12.56</td>
###xml 971 980 965 974 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">42 (36.8)</td>
###xml 980 990 974 984 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">100 (38.6)</td>
###xml 991 992 985 986 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 990 992 984 986 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1<sup>b</sup></td>
###xml 963 992 957 986 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">GG</td><td align="left">&lt;12.56</td><td align="left">42 (36.8)</td><td align="left">100 (38.6)</td><td align="left">1<sup>b</sup></td></tr>
###xml 992 994 986 988 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">GG</td>
###xml 994 1002 988 994 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#8805;12.56</td>
###xml 1002 1009 994 1001 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">7 (6.1)</td>
###xml 1009 1018 1001 1010 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">30 (11.6)</td>
###xml 1018 1034 1010 1026 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.66 (0.26&#8211;1.65)</td>
###xml 992 1034 986 1026 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">GG</td><td align="left">&#8805;12.56</td><td align="left">7 (6.1)</td><td align="left">30 (11.6)</td><td align="left">0.66 (0.26&#8211;1.65)</td></tr>
###xml 1034 1039 1026 1031 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">GT/TT</td>
###xml 1039 1045 1031 1037 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&lt;12.56</td>
###xml 1045 1054 1037 1046 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">47 (41.2)</td>
###xml 1054 1064 1046 1056 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">108 (41.7)</td>
###xml 1064 1080 1056 1072 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1.17 (0.69&#8211;1.96)</td>
###xml 1034 1080 1026 1072 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">GT/TT</td><td align="left">&lt;12.56</td><td align="left">47 (41.2)</td><td align="left">108 (41.7)</td><td align="left">1.17 (0.69&#8211;1.96)</td></tr>
###xml 1080 1085 1072 1077 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">GT/TT</td>
###xml 1085 1093 1077 1083 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#8805;12.56</td>
###xml 1093 1102 1083 1092 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">18 (15.8)</td>
###xml 1102 1110 1092 1100 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">21 (8.1)</td>
###xml 1110 1126 1100 1116 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">3.38 (1.46&#8211;7.84)</td>
###xml 1080 1126 1072 1116 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">GT/TT</td><td align="left">&#8805;12.56</td><td align="left">18 (15.8)</td><td align="left">21 (8.1)</td><td align="left">3.38 (1.46&#8211;7.84)</td></tr>
###xml 963 1126 957 1116 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">GG</td><td align="left">&lt;12.56</td><td align="left">42 (36.8)</td><td align="left">100 (38.6)</td><td align="left">1<sup>b</sup></td></tr><tr><td align="left">GG</td><td align="left">&#8805;12.56</td><td align="left">7 (6.1)</td><td align="left">30 (11.6)</td><td align="left">0.66 (0.26&#8211;1.65)</td></tr><tr><td align="left">GT/TT</td><td align="left">&lt;12.56</td><td align="left">47 (41.2)</td><td align="left">108 (41.7)</td><td align="left">1.17 (0.69&#8211;1.96)</td></tr><tr><td align="left">GT/TT</td><td align="left">&#8805;12.56</td><td align="left">18 (15.8)</td><td align="left">21 (8.1)</td><td align="left">3.38 (1.46&#8211;7.84)</td></tr></tbody>
###xml 886 1126 881 1116 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left"><italic>NOS3</italic> 894G&gt;T</th><th align="left">Plasma Hcy conc (&#956;mol/L)<sup>a</sup></th><th align="left">Mothers (%)</th><th align="left">Female controls (%)</th><th align="left">OR (95%CI)</th></tr></thead><tbody><tr><td align="left">GG</td><td align="left">&lt;12.56</td><td align="left">42 (36.8)</td><td align="left">100 (38.6)</td><td align="left">1<sup>b</sup></td></tr><tr><td align="left">GG</td><td align="left">&#8805;12.56</td><td align="left">7 (6.1)</td><td align="left">30 (11.6)</td><td align="left">0.66 (0.26&#8211;1.65)</td></tr><tr><td align="left">GT/TT</td><td align="left">&lt;12.56</td><td align="left">47 (41.2)</td><td align="left">108 (41.7)</td><td align="left">1.17 (0.69&#8211;1.96)</td></tr><tr><td align="left">GT/TT</td><td align="left">&#8805;12.56</td><td align="left">18 (15.8)</td><td align="left">21 (8.1)</td><td align="left">3.38 (1.46&#8211;7.84)</td></tr></tbody></table>
###xml 1126 1127 1116 1117 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1126 1257 1116 1247 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="43"><sup>a</sup>The 80th percentile of the control plasma homocysteine distribution was used to define elevated plasma homocysteine concentrations</p>
###xml 1257 1258 1247 1248 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 1257 1273 1247 1263 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="44"><sup>b</sup>Reference group</p>
###xml 1126 1273 1116 1263 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="43"><sup>a</sup>The 80th percentile of the control plasma homocysteine distribution was used to define elevated plasma homocysteine concentrations</p><p textid="44"><sup>b</sup>Reference group</p></table-wrap-foot>
###xml 745 1273 740 1263 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab4"><label>Table&#160;4</label><caption><p textid="42">Maternal spina bifida risk for the combination of the <italic>NOS3</italic> 894G&gt;T SNP and elevated plasma homocysteine concentration, adjusted for age</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><italic>NOS3</italic> 894G&gt;T</th><th align="left">Plasma Hcy conc (&#956;mol/L)<sup>a</sup></th><th align="left">Mothers (%)</th><th align="left">Female controls (%)</th><th align="left">OR (95%CI)</th></tr></thead><tbody><tr><td align="left">GG</td><td align="left">&lt;12.56</td><td align="left">42 (36.8)</td><td align="left">100 (38.6)</td><td align="left">1<sup>b</sup></td></tr><tr><td align="left">GG</td><td align="left">&#8805;12.56</td><td align="left">7 (6.1)</td><td align="left">30 (11.6)</td><td align="left">0.66 (0.26&#8211;1.65)</td></tr><tr><td align="left">GT/TT</td><td align="left">&lt;12.56</td><td align="left">47 (41.2)</td><td align="left">108 (41.7)</td><td align="left">1.17 (0.69&#8211;1.96)</td></tr><tr><td align="left">GT/TT</td><td align="left">&#8805;12.56</td><td align="left">18 (15.8)</td><td align="left">21 (8.1)</td><td align="left">3.38 (1.46&#8211;7.84)</td></tr></tbody></table><table-wrap-foot><p textid="43"><sup>a</sup>The 80th percentile of the control plasma homocysteine distribution was used to define elevated plasma homocysteine concentrations</p><p textid="44"><sup>b</sup>Reference group</p></table-wrap-foot></table-wrap>
Since the MTHFR 677C>T SNP is a genetic determinant of plasma folate and plasma homocysteine concentrations, possible interactions between the NOS3 894G>T SNP and these metabolites were examined in mothers. In combination with decreased plasma folate concentrations (<8.52 nmol/L), the NOS3 894GT/TT genotype did not increase maternal spina bifida risk relative to the NOS3 894GG genotype in combination with normal plasma folate concentrations (>/=8.52 nmol/L) (OR 1.14, 95%CI 0.49-2.67) (data not shown). The risk of having spina bifida affected offspring increased to 3.4-fold when the NOS3 894GT/TT genotype was present in combination with elevated plasma homocysteine concentrations (>/=12.56 mumol/L) (OR 3.38, 95%CI 1.46-7.84) (Table 4). Table 4Maternal spina bifida risk for the combination of the NOS3 894G>T SNP and elevated plasma homocysteine concentration, adjusted for ageNOS3 894G>TPlasma Hcy conc (mumol/L)aMothers (%)Female controls (%)OR (95%CI)GG<12.5642 (36.8)100 (38.6)1bGG>/=12.567 (6.1)30 (11.6)0.66 (0.26-1.65)GT/TT<12.5647 (41.2)108 (41.7)1.17 (0.69-1.96)GT/TT>/=12.5618 (15.8)21 (8.1)3.38 (1.46-7.84)aThe 80th percentile of the control plasma homocysteine distribution was used to define elevated plasma homocysteine concentrationsbReference group
###end p 41
###begin p 42
###xml 54 58 54 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
Maternal spina bifida risk for the combination of the NOS3 894G>T SNP and elevated plasma homocysteine concentration, adjusted for age
###end p 42
###begin p 43
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
aThe 80th percentile of the control plasma homocysteine distribution was used to define elevated plasma homocysteine concentrations
###end p 43
###begin p 44
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
bReference group
###end p 44
###begin title 45
Discussion
###end title 45
###begin p 46
###xml 19 23 19 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 150 154 150 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 201 206 201 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR</italic>
###xml 274 278 274 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
In this study, the NOS3 894TT genotype did not significantly increase spina bifida risk, and the TDT demonstrated no preferential transmission of the NOS3 894T allele. However, in combination with the MTHFR 677TT genotype or elevated plasma homocysteine concentrations, the NOS3 894GT/TT genotype increased maternal spina bifida risk 4.5- and 3.4-fold, respectively.
###end p 46
###begin p 47
###xml 85 89 85 89 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">2004</xref>
###xml 108 112 108 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 141 145 141 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 327 331 327 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">2004</xref>
###xml 383 387 383 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 448 452 448 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 533 537 533 537 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 589 593 589 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 740 744 740 744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">2004</xref>
Using a likelihood ratio test (LRT) for both proband and mother trios, Brown et al. (2004) demonstrated the NOS3 894GT genotype, but not the NOS3 894TT genotype, to be an embryonic risk factor for spina bifida (OR 1.63, 95%CI 1.09-2.42). Data from our case-control study might be in line with this observation of Brown et al. (2004); however, based on the effect of the heterozygous NOS3 894GT genotype on spina bifida risk, a larger effect of the NOS3 894TT genotype on spina bifida risk would be expected. The observation that the NOS3 894GT genotype increases spina bifida risk and the NOS3 894TT genotype does not could be explained as a chance finding, but could also be the result of lack of power, as also suggested by Brown et al. (2004).
###end p 47
###begin p 48
###xml 97 101 97 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 128 133 128 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR</italic>
###xml 277 281 277 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 426 430 426 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">2001</xref>
###xml 447 451 447 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">2000</xref>
###xml 507 511 507 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">2001</xref>
###xml 720 724 720 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">2004</xref>
###xml 750 754 750 754 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 936 937 936 937 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 1014 1018 1014 1018 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">1993</xref>
###xml 1071 1075 1071 1075 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">2004</xref>
###xml 1122 1123 1122 1123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 1197 1198 1197 1198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
Despite the small numbers on which the analyses are based, the possible interactions between the NOS3 894GT/TT genotype and the MTHFR 677TT genotype or elevated plasma homocysteine concentrations are interesting and may suggest a role for NOS3 uncoupling or S-nitrosation. The NOS3 894G>T SNP (Glu298Asp) has been suggested to impair NOS3 protein function and/or activity resulting in decreased NO production (Sofowora et al. 2001; Tesauro et al. 2000), although results are contradictory (Fairchild et al. 2001). Elevated homocysteine concentrations have been demonstrated to switch the NOS3 enzyme to an uncoupled state directed to the synthesis of reactive oxygen species (ROS) rather than NO synthesis (Topal et al. 2004). The combination of the NOS3 894GT/TT genotype and elevated plasma homocysteine concentrations may lead to such a decrease in NO levels that neurulation is hampered. NO can also react with homocysteine to form S-nitrosothiols, thereby modulating homocysteine availability (Stamler et al. 1993). As previously suggested by our group (Heil et al. 2004), decreased NO levels may result in decreased S-nitrosothiol formation, resulting in less capturing of homocysteine into S-nitrosoHcy. The subsequent increase in plasma homocysteine concentrations might influence proper neural tube closure, especially when plasma homocysteine concentrations are already high.
###end p 48
###begin p 49
###xml 42 46 42 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 239 243 239 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 300 304 300 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 117 122 <span type="species:ncbi:9606">child</span>
The results of our study suggest that the NOS3 894G>T SNP is a spina bifida risk factor in the mother and not in the child. Our results furthermore indicate a role for the homocysteine metabolism in the detrimental effects asserted by the NOS3 894G>T SNP. More studies on the association between the NOS3 894G>T SNP and spina bifida in larger populations are warranted.
###end p 49
###begin title 50
Acknowledgements
###end title 50
###begin p 51
This study was supported by the Prinses Beatrix Fonds, The Netherlands (MAR04-0121), the Dutch Kidney Foundation (C042083) and the NIH (1 R01 NS050249-01A1). Martin den Heijer is supported by The Netherlands Organization for Scientific Research (VENI grant NWO).
###end p 51
###begin title 52
References
###end title 52
###begin article-title 53
Genetic evidence that nitric oxide modulates homocysteine: the NOS3 894TT genotype is a risk factor for hyperhomocysteinemia
###end article-title 53
###begin article-title 54
Evidence that the risk of spina bifida is influenced by genetic variation at the NOS3 locus
###end article-title 54
###begin article-title 55
Nitric oxide inhibits methionine synthase activity in vivo and disrupts carbon flow through the folate pathway
###end article-title 55
###begin article-title 56
Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis?
###end article-title 56
###begin article-title 57
###xml 82 87 <span type="species:ncbi:9606">human</span>
Acidic hydrolysis as a mechanism for the cleavage of the Glu(298)->Asp variant of human endothelial nitric-oxide synthase
###end article-title 57
###begin article-title 58
The 894G>T variant of endothelial nitric oxide synthase (eNOS) increases the risk of recurrent venous thrombosis through interaction with elevated homocysteine levels
###end article-title 58
###begin article-title 59
A common variant of the endothelial nitric oxide synthase (Glu298->Asp) is a major risk factor for coronary artery disease in the UK
###end article-title 59
###begin article-title 60
###xml 153 154 153 154 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
Dysmorphogenic effects of nitric oxide (NO) and NO-synthase inhibition: studies with intra-amniotic injections of sodium nitroprusside and NG-monomethyl-l-arginine
###end article-title 60
###begin article-title 61
Shattuck lecture. Nitric oxide and cyclic GMP in cell signaling and drug development
###end article-title 61
###begin article-title 62
Neural tube closure depends on nitric oxide synthase activity
###end article-title 62
###begin article-title 63
Nitric oxide is involved in establishing the balance between cell cycle progression and cell death in the developing neural tube
###end article-title 63
###begin article-title 64
Genetic power calculator: design of linkage and association genetic mapping studies of complex traits
###end article-title 64
###begin article-title 65
In-vivo effects of Glu298Asp endothelial nitric oxide synthase polymorphism
###end article-title 65
###begin article-title 66
Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM)
###end article-title 66
###begin article-title 67
Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen
###end article-title 67
###begin article-title 68
Three different methods for the determination of total homocysteine in plasma.
###end article-title 68
###begin article-title 69
Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298.
###end article-title 69
###begin article-title 70
Homocysteine induces oxidative stress by uncoupling of NO synthase activity through reduction of tetrahydrobiopterin
###end article-title 70
###begin article-title 71
###xml 78 83 <span type="species:ncbi:9031">chick</span>
Evidence that nitric oxide regulates cell-cycle progression in the developing chick neuroepithelium
###end article-title 71
###begin article-title 72
###xml 59 67 <span type="species:ncbi:9606">children</span>
Hyperhomocysteinemia: a risk factor for ischemic stroke in children
###end article-title 72
###begin article-title 73
The methionine synthase reductase 66A>G polymorphism is a maternal risk factor for spina bifida
###end article-title 73
###begin article-title 74
Folic acid rescues nitric oxide-induced neural tube closure defects
###end article-title 74

